MA42456B1 - Inhibiteurs de hpk1 et leurs procédés d'utilisation - Google Patents
Inhibiteurs de hpk1 et leurs procédés d'utilisationInfo
- Publication number
- MA42456B1 MA42456B1 MA42456A MA42456A MA42456B1 MA 42456 B1 MA42456 B1 MA 42456B1 MA 42456 A MA42456 A MA 42456A MA 42456 A MA42456 A MA 42456A MA 42456 B1 MA42456 B1 MA 42456B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- methods
- formula
- pharmaceutically acceptable
- inhibitors
- Prior art date
Links
- 101100177670 Caenorhabditis elegans hpk-1 gene Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 230000005746 immune checkpoint blockade Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
L'invention concerne des composés de thiénopyridinone de formule (i) et des sels de ceux-ci pharmaceutiquement acceptables. Dans ces composés, l'un de x1, x2, et x3 est s et les deux autres sont chacun indépendamment cr, r et toutes les autres variables sont telles que définies dans la description. Ces composés sont connus pour inhiber l'activité de la kinase hpk1 et pour avoir une activité antitumorale in vivo. Ces composés peuvent être efficacement combinés avec des vecteurs pharmaceutiquement acceptables, ainsi qu'avec d'autres techniques immunomodulatrices, telles qu'une inhibition de points de contrôle ou des inhibiteurs de l'oxydation du tryptophane. Formule (i).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562184348P | 2015-06-25 | 2015-06-25 | |
PCT/CA2016/050734 WO2016205942A1 (fr) | 2015-06-25 | 2016-06-23 | Inhibiteurs de hpk1 et leurs procédés d'utilisation |
Publications (2)
Publication Number | Publication Date |
---|---|
MA42456A MA42456A (fr) | 2018-05-23 |
MA42456B1 true MA42456B1 (fr) | 2021-06-30 |
Family
ID=57584335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA42456A MA42456B1 (fr) | 2015-06-25 | 2016-06-23 | Inhibiteurs de hpk1 et leurs procédés d'utilisation |
Country Status (27)
Country | Link |
---|---|
US (3) | US10501474B2 (fr) |
EP (1) | EP3322711B1 (fr) |
JP (3) | JP6898868B2 (fr) |
KR (2) | KR102614872B1 (fr) |
CN (2) | CN107922431B (fr) |
AU (1) | AU2016282289B2 (fr) |
BR (2) | BR122023006150B1 (fr) |
CA (1) | CA2989684A1 (fr) |
CY (1) | CY1124489T1 (fr) |
DK (1) | DK3322711T3 (fr) |
EA (1) | EA035421B1 (fr) |
ES (1) | ES2872555T3 (fr) |
HK (1) | HK1255833A1 (fr) |
HR (1) | HRP20210895T1 (fr) |
HU (1) | HUE054159T2 (fr) |
IL (2) | IL283353B (fr) |
LT (1) | LT3322711T (fr) |
MA (1) | MA42456B1 (fr) |
MD (1) | MD3322711T2 (fr) |
MX (2) | MX2018000048A (fr) |
PL (1) | PL3322711T3 (fr) |
PT (1) | PT3322711T (fr) |
RS (1) | RS61919B1 (fr) |
SG (1) | SG10202105964RA (fr) |
SI (1) | SI3322711T1 (fr) |
TW (1) | TWI733679B (fr) |
WO (1) | WO2016205942A1 (fr) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR122023006150B1 (pt) * | 2015-06-25 | 2023-12-12 | University Health Network | Compostos inibidores de hpk1, seu uso, e composição farmacêutica que os compreende |
CN115819417A (zh) | 2016-09-09 | 2023-03-21 | 因赛特公司 | 作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途 |
TW201811799A (zh) | 2016-09-09 | 2018-04-01 | 美商英塞特公司 | 吡唑并嘧啶化合物及其用途 |
US10280164B2 (en) | 2016-09-09 | 2019-05-07 | Incyte Corporation | Pyrazolopyridone compounds and uses thereof |
WO2018049214A1 (fr) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Dérivés de pyrazolopyridine comme modulateurs de hpk1 et leurs utilisations pour le traitement du cancer |
WO2018152220A1 (fr) | 2017-02-15 | 2018-08-23 | Incyte Corporation | Composés de pyrazolopyridine et leurs utilisations |
WO2018167147A1 (fr) * | 2017-03-15 | 2018-09-20 | F. Hoffmann-La Roche Ag | Azaindoles utilisés en tant qu'inhibiteurs de hpk1 |
JP7154221B2 (ja) | 2017-03-30 | 2022-10-17 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Hpk1の阻害剤としてのナフチリジン |
CN110709392B (zh) | 2017-03-30 | 2023-09-29 | 豪夫迈·罗氏有限公司 | 作为hpk1抑制剂的异喹啉 |
WO2018228923A1 (fr) | 2017-06-13 | 2018-12-20 | Bayer Pharma Aktiengesellschaft | Dérivés de pyrrolopyridine substitués utilisés en tant que modulateurs de map4k1 pour le traitement de maladies cancéreuses |
CA3066859A1 (fr) | 2017-06-13 | 2018-12-20 | Bayer Pharma Aktiengesellschaft | Derives de pyrrolopyridine substitues |
WO2018228925A1 (fr) | 2017-06-13 | 2018-12-20 | Bayer Pharma Aktiengesellschaft | Dérivés de pyrrolopyridine substitués |
EP3655406A1 (fr) | 2017-07-18 | 2020-05-27 | Bayer Pharma Aktiengesellschaft | Dérivés de pyrrolopyridine substitués |
WO2019051199A1 (fr) * | 2017-09-08 | 2019-03-14 | Incyte Corporation | Composés de 6-cyano-indazole utilisés en tant que modulateurs de kinase 1 progénitrices hématopoïétiques (hpk1) |
CN109721620B (zh) * | 2017-10-27 | 2022-05-13 | 药捷安康(南京)科技股份有限公司 | Hpk1抑制剂及其用途 |
KR20200085303A (ko) * | 2017-11-06 | 2020-07-14 | 브리스톨-마이어스 스큅 컴퍼니 | Hpk1 억제제로서 유용한 이소푸라논 화합물 |
US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
CR20200421A (es) * | 2018-02-20 | 2021-01-26 | Incyte Corp | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el càncer |
US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
JP7386841B2 (ja) * | 2018-07-24 | 2023-11-27 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | イソキノリン化合物及びその使用 |
WO2020023551A1 (fr) * | 2018-07-24 | 2020-01-30 | Genentech, Inc. | Composés de naphtyridine et leurs utilisations |
US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
MA53726A (fr) | 2018-09-25 | 2022-05-11 | Incyte Corp | Composés pyrazolo[4,3-d]pyrimidine en tant que modulateurs des alk2 et/ou fgfr |
TW202024053A (zh) * | 2018-10-02 | 2020-07-01 | 美商建南德克公司 | 異喹啉化合物及其用途 |
CN113166062A (zh) * | 2018-10-03 | 2021-07-23 | 豪夫迈·罗氏有限公司 | 8-氨基异喹啉化合物及其用途 |
US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
CN117105933A (zh) * | 2018-10-31 | 2023-11-24 | 吉利德科学公司 | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |
HRP20240541T1 (hr) | 2018-10-31 | 2024-07-05 | Gilead Sciences, Inc. | Supstituirani spojevi 6-azabenzimidazola kao inhibitori hpk1 |
WO2020120257A1 (fr) | 2018-12-11 | 2020-06-18 | Bayer Aktiengesellschaft | Dérivés de pyrrolopyridine substitués |
WO2020132384A1 (fr) | 2018-12-21 | 2020-06-25 | Celgene Corporation | Inhibiteurs thiénopyridine de ripk2 |
JP2022515622A (ja) * | 2018-12-26 | 2022-02-21 | ヤンセン ファーマシューティカ エヌ.ベー. | チエノピリジノン化合物 |
WO2020193512A1 (fr) | 2019-03-26 | 2020-10-01 | Janssen Pharmaceutica Nv | Inhibiteurs bicycliques de hpk1 |
TW202102488A (zh) | 2019-03-26 | 2021-01-16 | 比利時商健生藥品公司 | Hpk1抑制劑 |
US20220242870A1 (en) * | 2019-05-17 | 2022-08-04 | Voronoi Inc. | Heterocycle-fused pyrimidine derivative and use thereof |
TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
WO2020263830A1 (fr) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Protéines de fusion flt3l-fc et procédés d'utilisation |
BR112022002059A2 (pt) | 2019-08-06 | 2022-06-07 | Incyte Corp | Formas sólidas de um inibidor de hpk1 |
WO2021050964A1 (fr) * | 2019-09-13 | 2021-03-18 | Nimbus Saturn, Inc. | Antagonistes de hpk1 et leurs utilisations |
CN112552293A (zh) * | 2019-09-25 | 2021-03-26 | 珠海宇繁生物科技有限责任公司 | 一种protac小分子化合物及其应用 |
US11795223B2 (en) | 2019-10-18 | 2023-10-24 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
WO2021087064A1 (fr) | 2019-10-31 | 2021-05-06 | Forty Seven, Inc. | Traitement d'un cancer du sang basé sur une thérapie anti-cd47 et anti-cd20 |
TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
BR112022012625A2 (pt) | 2019-12-24 | 2022-09-06 | Carna Biosciences Inc | Compostos moduladores de diacilglicerol quinase |
WO2021141106A1 (fr) * | 2020-01-09 | 2021-07-15 | 住友化学株式会社 | Composé hétérocyclique et composition de lutte contre les arthropodes nuisibles le comprenant |
CN117964757A (zh) | 2020-02-14 | 2024-05-03 | 吉利德科学公司 | 与ccr8结合的抗体和融合蛋白及其用途 |
TW202203917A (zh) * | 2020-04-13 | 2022-02-01 | 加拿大健康網路大學 | 治療細胞激素釋放症候群之方法 |
US20240043427A1 (en) | 2020-05-01 | 2024-02-08 | Gilead Sciences, Inc. | Cd73 compounds |
BR112022022946A2 (pt) * | 2020-05-11 | 2023-01-10 | Univ Health Network | Sal e formas cristalinas de 4-amino-5-(6-(4-metilpiperazin-1-il)-1h-benzo[d]imidazol-2-il)tieno[2,3-b]piridin-6(7h)-ona |
WO2021249913A1 (fr) | 2020-06-09 | 2021-12-16 | Bayer Aktiengesellschaft | Dérivés de 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azétidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate et des composés apparentés servant d'inhibiteurs de map4k1 (hpk1) pour le traitement du cancer |
JP2023543212A (ja) * | 2020-09-30 | 2023-10-13 | ベイジーン リミテッド | Hpk1阻害剤としての3-[(1h-ピラゾール-4-イル)オキシ]ピラジン-2-アミン化合物及びその使用 |
US20230406864A1 (en) * | 2020-11-09 | 2023-12-21 | Merck Sharp & Dohme Llc | 7-azole substituted 2-aminoquinazoline inhibitors of hpk1 |
JP2023550380A (ja) * | 2020-11-24 | 2023-12-01 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | 重水素修飾チエノピリドン化合物 |
WO2022167627A1 (fr) | 2021-02-05 | 2022-08-11 | Bayer Aktiengesellschaft | Inhibiteurs de map4k1 |
JP2024509192A (ja) | 2021-03-05 | 2024-02-29 | ニンバス サターン, インコーポレイテッド | Hpk1アンタゴニスト及びその使用 |
WO2022188823A1 (fr) * | 2021-03-10 | 2022-09-15 | 山东轩竹医药科技有限公司 | Inhibiteur de hpk1 tricyclique et son utilisation |
CN116981666A (zh) * | 2021-03-26 | 2023-10-31 | 江苏恒瑞医药股份有限公司 | 稠合四环类化合物、其制备方法及其在医药上的应用 |
TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症 |
WO2022226667A1 (fr) * | 2021-04-30 | 2022-11-03 | Ontario Institute For Cancer Research (Oicr) | Composés aminopyridine substitués utilisés en tant qu'inhibiteurs de la kinase progénitrice hématopoïétique 1 (hpk1) |
WO2022245671A1 (fr) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Méthodes d'utilisation de protéines de fusion flt3l-fc |
WO2022253252A1 (fr) * | 2021-06-03 | 2022-12-08 | Silexon Biotech Co., Ltd. | Composés hétérocycliques utiles en tant qu'inhibiteurs de hpk1 |
CN115433161A (zh) * | 2021-06-04 | 2022-12-06 | 轶诺(浙江)药业有限公司 | 新型hpk1抑制剂及其制备方法和应用 |
CN117355531A (zh) | 2021-06-23 | 2024-01-05 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
EP4359411A1 (fr) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Composés modulant les diacylglycérol kinases |
MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
WO2023001794A1 (fr) | 2021-07-20 | 2023-01-26 | Astrazeneca Ab | Pyrazine-2-carboxamides substituées utilisées en tant qu'inhibiteurs de hpk1 pour le traitement du cancer |
WO2023015199A1 (fr) * | 2021-08-03 | 2023-02-09 | Nimbus Saturn, Inc. | Antagonistes de hpk1 et leurs utilisations |
WO2023023942A1 (fr) * | 2021-08-24 | 2023-03-02 | Biofront Ltd (Cayman) | Inhibiteurs de hpk1, compositions comprenant un inhibiteur de hpk1 et leurs procédés d'utilisation |
WO2023057882A1 (fr) * | 2021-10-05 | 2023-04-13 | Pfizer Inc. | Combinaisons de composés d'azalactam avec un antagoniste de liaison à l'axe pd-1 pour le traitement du cancer |
WO2023064133A1 (fr) * | 2021-10-15 | 2023-04-20 | Lomond Therapeutics, Inc. | 1h-pyrazolo[4,3-c]quinoléines substituées, leurs procédés de préparation et leur utilisation |
WO2023076983A1 (fr) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Dérivés de pyridine-3(2h)-one |
CN118201941A (zh) | 2021-10-29 | 2024-06-14 | 吉利德科学公司 | Cd73化合物 |
WO2023107956A1 (fr) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Protéines se liant à nkg2d, cd16 et 5t4 |
WO2023107954A1 (fr) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Anticorps ciblant 5t4 et leurs utilisations |
WO2023109902A1 (fr) * | 2021-12-17 | 2023-06-22 | 海思科医药集团股份有限公司 | Dérivé hétérocyclique fusionné et son utilisation en médecine |
CA3237577A1 (fr) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Agents de degradation des doigts de zinc de la famille ikaros et leurs utilisations |
TW202333712A (zh) * | 2021-12-22 | 2023-09-01 | 加拿大健康網路大學 | 於急性骨髓性白血病或淋巴瘤之治療 |
WO2023122581A2 (fr) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Agents de dégradation de doigt de zinc de la famille ikaros et utilisations associées |
WO2023138612A1 (fr) * | 2022-01-19 | 2023-07-27 | Silexon Ai Technology Co., Ltd. | Composés hétérocycliques utiles en tant qu'inhibiteurs de hpk1 |
WO2023143384A1 (fr) * | 2022-01-27 | 2023-08-03 | 四川海思科制药有限公司 | Composé pour inhiber ou dégrader la kinase hpk1 et son utilisation médicale |
TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7抑制劑 |
CN116462685A (zh) * | 2022-02-08 | 2023-07-21 | 和径医药科技(上海)有限公司 | 杂环化合物、包含其的药物组合物及其抗肿瘤应用 |
US20230373950A1 (en) | 2022-03-17 | 2023-11-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023183817A1 (fr) | 2022-03-24 | 2023-09-28 | Gilead Sciences, Inc. | Polythérapie pour le traitement de cancers exprimant trop -2 |
TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
WO2023205719A1 (fr) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Composés modulateurs de kras g12d |
US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
WO2024064668A1 (fr) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | POLYTHÉRAPIE ANTICANCÉREUSE PAR RAYONNEMENT IONISANT FOCAL ET PERTURBATION CD47/SIRPα |
KR20240077873A (ko) | 2022-11-25 | 2024-06-03 | 충남대학교산학협력단 | 이미다조피리딘 유도체, 이를 유효성분으로 포함하는 약제학적 조성물 및 이를 이용하는 암의 치료 방법 |
WO2024137852A1 (fr) | 2022-12-22 | 2024-06-27 | Gilead Sciences, Inc. | Inhibiteurs de prmt5 et leurs utilisations |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001021615A1 (fr) * | 1999-09-17 | 2001-03-29 | Yamanouchi Pharmaceutical Co., Ltd. | Dérivés de benzimidazole |
EP1226119B1 (fr) * | 1999-10-19 | 2005-03-16 | MERCK & CO. INC. | Inhibiteurs tyrosine kinase |
AU2001293233A1 (en) * | 2000-09-01 | 2002-03-13 | Chiron Corporation | Aza heterocyclic derivatives and their therapeutic use |
WO2004014375A2 (fr) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Inhibiteurs de metalloprotease bicycliques condenses |
US7119205B2 (en) | 2003-05-16 | 2006-10-10 | Abbott Laboratories | Thienopyridones as AMPK activators for the treatment of diabetes and obesity |
US8501750B2 (en) | 2007-05-21 | 2013-08-06 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
UA103321C2 (ru) * | 2008-04-11 | 2013-10-10 | Мерк Патент Гмбх | Производные тиенопиридона как активаторы amp-активированной протеинкиназы (амрк) |
KR101648593B1 (ko) | 2008-05-05 | 2016-08-16 | 메르크 파텐트 게엠베하 | Amp-활성화된 단백질 키나아제 (ampk) 활성화제로서의 티에노피리돈 유도체 |
MX2013008822A (es) | 2011-02-09 | 2013-10-07 | Hoffmann La Roche | Compuestos heterociclicos como inhibidores de cinasa fosfatidilinositol-3 (pi3). |
GB201114212D0 (en) * | 2011-08-18 | 2011-10-05 | Ucb Pharma Sa | Therapeutic agents |
BR122023006150B1 (pt) * | 2015-06-25 | 2023-12-12 | University Health Network | Compostos inibidores de hpk1, seu uso, e composição farmacêutica que os compreende |
-
2016
- 2016-06-23 BR BR122023006150-0A patent/BR122023006150B1/pt active IP Right Grant
- 2016-06-23 IL IL283353A patent/IL283353B/en unknown
- 2016-06-23 PT PT168134377T patent/PT3322711T/pt unknown
- 2016-06-23 LT LTEP16813437.7T patent/LT3322711T/lt unknown
- 2016-06-23 MD MDE20180529T patent/MD3322711T2/ro unknown
- 2016-06-23 CN CN201680048058.0A patent/CN107922431B/zh active Active
- 2016-06-23 SI SI201631189T patent/SI3322711T1/sl unknown
- 2016-06-23 ES ES16813437T patent/ES2872555T3/es active Active
- 2016-06-23 CN CN202110534553.5A patent/CN113214287B/zh active Active
- 2016-06-23 PL PL16813437T patent/PL3322711T3/pl unknown
- 2016-06-23 MA MA42456A patent/MA42456B1/fr unknown
- 2016-06-23 SG SG10202105964RA patent/SG10202105964RA/en unknown
- 2016-06-23 KR KR1020187001327A patent/KR102614872B1/ko active IP Right Grant
- 2016-06-23 EP EP16813437.7A patent/EP3322711B1/fr active Active
- 2016-06-23 HU HUE16813437A patent/HUE054159T2/hu unknown
- 2016-06-23 EA EA201890059A patent/EA035421B1/ru not_active IP Right Cessation
- 2016-06-23 MX MX2018000048A patent/MX2018000048A/es unknown
- 2016-06-23 US US15/738,286 patent/US10501474B2/en active Active
- 2016-06-23 DK DK16813437.7T patent/DK3322711T3/da active
- 2016-06-23 RS RS20210675A patent/RS61919B1/sr unknown
- 2016-06-23 WO PCT/CA2016/050734 patent/WO2016205942A1/fr active Application Filing
- 2016-06-23 CA CA2989684A patent/CA2989684A1/fr active Pending
- 2016-06-23 JP JP2017566338A patent/JP6898868B2/ja active Active
- 2016-06-23 KR KR1020237042987A patent/KR20240000617A/ko not_active Application Discontinuation
- 2016-06-23 BR BR112017027241-5A patent/BR112017027241B1/pt active IP Right Grant
- 2016-06-23 AU AU2016282289A patent/AU2016282289B2/en active Active
- 2016-06-24 TW TW105120043A patent/TWI733679B/zh active
-
2017
- 2017-12-11 IL IL256250A patent/IL256250B/en active IP Right Grant
-
2018
- 2018-01-08 MX MX2021011435A patent/MX2021011435A/es unknown
- 2018-11-21 HK HK18114909.1A patent/HK1255833A1/zh unknown
-
2019
- 2019-12-06 US US16/705,458 patent/US11059832B2/en active Active
-
2021
- 2021-06-07 HR HRP20210895TT patent/HRP20210895T1/hr unknown
- 2021-06-08 CY CY20211100498T patent/CY1124489T1/el unknown
- 2021-06-11 JP JP2021097834A patent/JP7241810B2/ja active Active
- 2021-07-12 US US17/372,717 patent/US20220002313A1/en active Pending
-
2023
- 2023-03-07 JP JP2023034474A patent/JP2023071911A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA42456B1 (fr) | Inhibiteurs de hpk1 et leurs procédés d'utilisation | |
MA39554A3 (fr) | Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock | |
ZA202101960B (en) | Protein tyrosine phosphatase inhibitors | |
MA42410B1 (fr) | Oxystérols et leurs méthodes d'utilisation | |
MA38393B1 (fr) | Composés hétéroaryle et utilisations associées | |
MA37762A1 (fr) | Composés n-aryltriazole utilisés comme antagonistes de lpar | |
MA37764A1 (fr) | Composés n-alkyltriazole utilisés comme antagonistes de lpar | |
MA52492B1 (fr) | Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés | |
PH12013502369A1 (en) | Diazacarbazoles and methods of use | |
MA32134B1 (fr) | Composés hétérocycliques | |
MA29856B1 (fr) | Derives de diacylindazole en tant qu'inhibiteurs de lipases et de phospholipases | |
PH12017500841A1 (en) | 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
MA34234B1 (fr) | Composes pyrazol-4-yl-heterocyclyle-carboxamide et leurs procedes d'utilisation | |
MA43468A1 (fr) | Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2 | |
MA32901B1 (fr) | Composes utiles pour l'inhibition de la chk1 | |
MX2018013164A (es) | Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa. | |
SG156681A1 (en) | Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure | |
MA50013B1 (fr) | Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton | |
EA201892514A1 (ru) | Промежуточные соединения для синтеза производных желчных кислот, в частности обетихолевой кислоты | |
AU2020258568A8 (en) | CD73 inhibitors | |
SG10201909382UA (en) | Glyt1 inhibitors for use in the treatment of hematological disorders | |
MA38009B1 (fr) | Composes d'azaindoline substitues qui ont une activite inhibitrice de la proteine d'apoptose pour leurs utilisations dans le traitement et/ou la prophylaxie du cancer | |
MX2021002878A (es) | Inhibidores de cd73 y usos farmaceuticos de los mismos. | |
TNSN07355A1 (fr) | Derives d'aryl-1,4-pyrazine substitues | |
WO2012107735A3 (fr) | Traitement de trouble bipolaire |